The NPS landscape is changing rapidly, requiring laboratories to constantly remain abreast of new and emerging drugs locally, nationally, and internationally. To meet individualized needs, laboratories amend existing methods or develop new ones for detection and confirmation of NPS. This can be challenging for scientists as information about NPS detections can be regionalized and/or out-of-date, making it difficult to determine which drugs should be prioritized at a given time. CFSRE’s NPS Discovery and the SOFT NPS Committee have established the below recommendations for NPS scope based on information from extensive collaborations, partnerships, and initiatives which yield national and international perspectives. Suggested cut-off concentrations or reporting limits (in ng/mL) are listed for each NPS. These values are categorized (i.e., <1, 1-10, and >10 ng/mL) and determined based on currently available quantitative data and/or comparison to structurally similar NPS within the given sub-class. (Publisher abstract provided.)
Downloads
Similar Publications
- Designer Fentanyl Precursors Leading the Way to New Fentanyl Analogs—The Case of ortho-Methylfentanyl
- Application of the Optimized Summed Scored Attributes Method to Sex Estimation in Asian Crania
- Advancing genotype-phenotype analysis through 3D facial morphometry: insights from Cri-du-Chat syndrome